ArticleFrontiers in veterinary science2025
Post-carvedilol myocardial function in cats with obstructive hypertrophic cardiomyopathy.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of myocardial function by strain echocardiography in cats with hypertrophic cardiomyopathy phenotypes.Veterinary world · 2026Article
- Efficacy of high-dose carvedilol treatment for cats with stage B1 obstructive hypertrophic cardiomyopathy.Journal of feline medicine and surgery · 2026Article
- Disopyramide Therapy in Cats with Obstructive Hypertrophic Cardiomyopathy Non-Responsive to Carvedilol.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats, and one phenotype includes obstructive HCM with dynamic left ventricular outflow tract obstruction (DLVOTO). Myocardial function has been reported to be lower in cats with obstructive HCM than in non-obstructive HCM. Carvedilol, because of its pharmacological action, is expected to reduce the pressure gradient associated with DLVOTO, but no previous reports have studied its effects on myocardial function. This study aimed to evaluate myocardial function in cats with obstructive HCM with left ventricular outflow tract obstruction treated by carvedilol administration. Methods: This retrospective observational study included 16 cats with obstructive HCM and subsequent treatment of DLVOTO with carvedilol. In addition to conventional echocardiography, strain and strain rates in the left ventricular longitudinal and circumferential directions were measured using layer-specific two-dimensional speckle tracking echocardiography. Each variable was then compared before and after carvedilol medication. Results: Systolic anterior motion of the mitral valve disappeared in 14 cats and all cats showed resolved DLVOTO with maximal left ventricular outflow tract blood flow velocity of <2.5 m/s after carvedilol administration ( Conclusion: Treatment of obstructive HCM with carvedilol improved DLVOTO and myocardial function without a negative inotropic effect. Carvedilol may be effective in treating cats with obstructive HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.